

FORM PTO-1390 (REV 12-29-99)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 8737-000007	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/529653	
INTERNATIONAL APPLICATION NO. PCT/CN98/00209		INTERNATIONAL FILING DATE September 30, 1998		PRIORITY DATE CLAIMED October 17, 1997	
TITLE OF INVENTION GINKGO BILOBA L. LEAVES CIGARETTE					
APPLICANT(S) FOR DO/EO/US Yong Zou					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 					
Items 11. to 16. below concern document(s) or information included:					
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: Express Mailing Certificate (Label No. EK600175737US) and acknowledgement postcard 					

U.S. APPLICATION NO. (if known, see 37 CFR 1.52) <div style="font-size: 24pt; font-weight: bold;">09/529653</div>		INTERNATIONAL APPLICATION NO. PCT/CN98/00209		ATTORNEY'S DOCKET NUMBER 8737-000007	
----------------------------------------------------------------------------------------------------------------------	--	-------------------------------------------------	--	-----------------------------------------	--

17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00 <div style="text-align: right; font-weight: bold;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				CALCULATIONS PTO USE ONLY	
				\$ 970.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input checked="" type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	1 - 20 =	0	X \$18.00	\$ 0.00	
Independent claims	1 - 3 =	0	X \$78.00	\$ 0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$ 0.00	
TOTAL OF ABOVE CALCULATIONS =				\$1100.00	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$1100.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$1100.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$1100.00	
				Amount to be refunded:	\$
				charged:	\$

a. ☒ A check in the amount of \$ 1,100.00 to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 08-0750. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

HARNESS, DICKEY & PIERCE, P.L.C.
 P.O. Box 828
 Bloomfield Hills, MI 48303
 (248) 641-1600


 SIGNATURE:
Thomas T. Moga
 NAME
34,881
 REGISTRATION NUMBER



Attorney Docket No. 8737-000007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit:

Examiner:

Inventor(s): Yong Zou and Qiang Zou

Serial Number: 09/529,653

Filed: April 17, 2000

For: GINKGO BILOBA L. LEAVES CIGARETTE

Patent No.

Issued:

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) AND 1.27(b)) - INDEPENDENT INVENTOR**

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention described in

- ☐ the specification filed herewith.
- ☒ the application whose serial number is set forth above.
- ☐ the patent set forth above.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not likewise be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Signature Yong Zou
(Typed Name) Yong Zou

Date June/06/2000

Signature Qiang Zou
(Typed Name) Qiang Zou

Date June/06/2000

Signature _____
(Typed Name) _____

Date _____

Attorney Docket No. 8737-000007

GINKGO BILOBA L. LEAVES CIGARETTE

Technology Field of the Invention

This invention relates to a kind of cigarette substitute, particularly, Ginkgo biloba L. leaves cigarette in order to provide a new kind of cigarette for society.

Background of the Invention

Many investigations and experiments have proved that smoking is harmful to people's health.

While all the governments of the world are advocating quitting smoking and making laws to limit the producing and selling of cigarettes, scientists and tobacco technicians are making efforts to study how to lessen the cigarette's harm and develop low harm or harmless cigarettes. It is because that there are too many smokers, the complete prohibition of smoking achieved little effect. On social effect and economic return, the contradictions, smoking and health, are still existing.

In the field of production, the filter technology is usually adopted to eliminate the poisonous substances from cigarettes. Most kinds of cigarette filters are made of active charcoal fibre or vinegar acidity fibre

(see CN2174854Y and CN/088763A). Another method is in connection with cut tobacco itself. That is to treat the cut tobacco by special process (see CN 1045515A).

5 However, these ordinary methods mentioned above cannot solve the problems thoroughly.

To prevent and cure diseases, people have so far developed Argy wormwood leaf cigarette, Tea cigarette, Fiveleaf Gynostemma Herb cigarette and mixed herbal cigarette which is produced by adding eucalyptus, Dogbance leaf, Pilose Asiabell Root, Wild Mint Herb, Slen
10 derstyle Acanthopanax Root-bark, Changbai Ginseng, Fritillary Bulb, Milkvetch Root, Tremella, Lucid Ganoderma, Radish, Dwarf Lilyturf Tuber, Tall Gastraodia Tuber, Eucommia Bark, Hempleaf Negundo Chastetree, Coral and Ginger into tobacco. However, these cigarettes are not satisfactory in respect of cost, medical effect, and low
15 poisonousness. People are trying to develop a new kind of cigarette substitute which is satisfactory in the respects of cost, taste and poisonousness.

Ginkgo biloba L., which is dioecious, is of gymnosperm. It originally grows in China. Ginkgo biloba L. is the oldest tree species in
20 the world, even older than dinosaur, so it is called "live fossil". It has great vitality. In 1966 German scientist W. Schwabe discovered that

Ginkgo biloba L Leaves contain some active substances-Flavonoids and Ginkgolide, which can prevent and care angiocardopathy and nerve system diseases. From then on, the modern study on Ginkgobiloba L. Leaves' pharmacological property and application began. Scientific researches proved that Ginkgo biloba L. leaves contain a large amount of flavonoids and Ginkgolide A, B and C. Flavonoides are especially effective in curing angiocardopathy and are widely used at present. The can make the sclerosed blood vessels recover elasticity, improve the brittleness of blood vessels, dilate blood vessels and prevent the atrophy of organ functions caused by the bad circulation of blood. Ginkgolide is specific platelet activating factor antagonist. (PAF is one of the mediums of the paroxysm of many diseases.) It has the functions of making blood active and minimizing the cholesterin content in blood. It also can be used to prevent and cure the allergic diseases of breath tract. Bilobalide can straighten out cranial nerve streak and has the functions of refreshing, resisting fatigue and intensifying memory. In 1991, a Harvard scholar won the Nobel Prize for successfully synthesizing Bilobalide in laboratory. Scientists and medical experts have proved by animal experiments that many pharmaceutical substances in Ginkgo biloba L. leaves have important effects on deterring senescence and resisting diseases. Therefore,

many developed countries such as America, Korea and some European countries are speeding up to develop Ginkgo biloba Extract.

In China, several kinds of Ginkgo biloba medicines have been developed. China is the main producing country of Ginkgo biloba L. leaves, and however, the development on Ginkgo biloba L. leaves product is still in its beginning stages.

Ginkgo biloba L. leaves contain plentiful fibres. The cigarette substitute made of dry Ginkgo biloba L. leaves burns continuously and fully. Its ashes are white and fine. Its smoke is soft and dense. It taste is good and its smell is fragrant and sweet. Its pharmaceutical active ingredients volatilize continuously at the same time of burning.

As a cigarette substitute, Ginkgo biloba L. leaves cigarette also has obvious function of refreshing, but its principle is different from that of the ordinary cigarette. The smoke of the ordinary cigarette contains nicotine which can stimulate brain nerves to be excited, and make people become addicted to it. The smoke of Ginkgo biloba L. leaves cigarette contains Bilobalide and other pharmaceutical active ingredients which can stimulate the brain nerve and straighten out cranial nerve system, having function of refreshing and resisting fatigue. It doesn't contain any nicotine at all. Therefore, Ginkgo biloba L. leaves cigarette is not only an excellent cigarette substitute, but also an ideal product for

quitting smoking. A tobacco addict can successfully quit smoking with no agony by smoking Ginkgo biloba L. cigarette.

5 In view of the above-mentioned factors, Ginkgo biloba L. leaves can do good to human bodies. It contains the pharmaceutical active ingredients which can volatilize easily and its smokable property is similar to tobacco cigarette, so it is hopeful to take the place of the cigarette which contains nicotine.

10 A poisonousness-reduced cigarette and its producing process are disclosed in reference CN1140036A. This kind of cigarette contains the solution extract of Ginkgo biloba L. leaves, Leech, Szechwan Lovage Rhizome and other three substances. What is worth mentioning is that the substances mentioned above are sprayed onto the cut tobacco in the form of solution.

15 After the long-period study of the inventor, a kind of Ginkgo biloba L. leaves cigarette has been developed. The raw material is Ginkgo biloba L. leaves, containing little or no tobacco. Therefore it is good to people's health and is completely different from the cigarette introduced in reference CN1140036A. As mentioned above, the cigarette's raw material of the latter is tobacco, and the solution extract
20 is sprayed onto its surface. It is obvious that the nicotine content can not lowered at all.

Summary of the Invention

The object of this invention is to produce Ginkgo biloba L. leaves cigarette using Ginkgo biloba L. leaves and to provide people with a kind of cigarette substitute which has functions of the ordinary cigarette, while it is good to people's health. It will help people to go far away from tobacco and avoid the harm brought by smoking. Ginkgo biloba L. leaves are the main material of this kind of cigarette, and, if necessary, ^{or other tobacco-used herbs} tobacco can optionally be added therein according to special requirements.

Detailed Description of the Preferred Embodiments

One embodiment of this invention is to pick fresh Ginkgo biloba L. leaves from trees, process them into threads, then replace tobacco with 100 wt % dry material of this kin. Another embodiment is to blend dry Ginkgo biloba L. leaves with a percentage of more than 50 weight and ^{or other tobacco-used herbs} tobacco with a percentage of less than 50 weight together.

The process therefor includes producing pure Ginkgo biloba L. leaves cigarette or complex Ginkgo biloba L. leaves cigarette by means of ordinary process for producing cigarette.

Example 1

Use ~~dry~~ processed Ginkgo biloba L. leaves, ^{dry-cured} ~~flue-cure~~ them, then cut them into threads after moist-cured by means of ordinary process for producing cigarette.

the pure Ginkgo biloba L. leaves cigarette can be produced.

5 Example 2

Use ~~dry~~ processed Ginkgo biloba L. leaves, flue-cure them, then cut them into threads or pieces after moist-cured. Using the ordinary cigar wrappers, the Ginkgo biloba L. leaves cigar can be produced.

Example 3

10 Use ~~dry~~ processed Ginkgo biloba L. leaves 50Kg, cut them into threads or pieces after moist-cured, then add ordinary tobacco 5Kg, then blend them together. By means of the ordinary process for producing cigarette, the mixed cigarette can be produced.

Test Example 1

15 1. object of the test:

To test mouse peroral toxicity of Ginkgo biloba L. leaves cigarette.

2. Material and method: Horn method is adopted.

Use Mice of Qunming (a province of China) species provided by standard animal laboratory, 18~21 g weight, and half male and half female. The samples to be tested are made up with distilled water, orally fill into stomach in one dose, and observe them for one week.

3. Result

dosage	10000	4640	2150	1000mg/Kg
female	0/5	0/5	0/5	0/5
male	0/5	0/5	0/5	0/5

Adopting Horn method, the result is as below: LD50 of this sample is higher than 10000mg/Kg.

4. Conclusion: The sample is non-toxic.

Test Example 2: Flue gas analysis.

Test Content: Nicotine content.

Based Standards of Test: GB/T5606.1 5606.2-1996

GB5606.3-5606.6-1996

YC/T28.28.12-1996

Average Smoke Times: 14.6

Moisture Content (mg/cigarette): 2.24

Nicotine (mg/cigarette): 0.00

Conclusion: There is no nicotine in the smoke.

Industrial Applicability

Because the flavolides, Ginkgolide and bilobalide contained in
5 Ginkgo biloba L. leaves are easy to volatilize, and while the cigarette is
burning the temperature is becoming lower and lower from the burning
end to the filter, the pharmaceutical active ingredients contained in the
cigarette can volatilize with smoke before being destroyed for being
overheated. These ingredients are absorbed into human body and go
10 into blood circulation by lung. Smoking Ginkgo biloba L. leaves have
obvious effects on preventing hypertension and angiocardopathy,
recovering from fatigue, refreshing, stimulating appetite and improving
sleep. Long-term smoking of this kind of cigarette substitute can
prevent and cure senile dementia disease, hypertension, heart disease,
15 arteriosclerosis, cerebral and brain function failing. It is helpful to
intensify memory, build up a good physique and deter senescence.

The pure Ginkgo biloba L. leaves cigarette has a good taste, the
passive smoker can easily smell its fragrance. As containing no
tobacco, it can avoid the harm brought by nicotine and can be used as
20 an ideal product for quitting smoking tobacco cigarette.

Therefore, the invention of Ginkgo biloba L. leaves is very important to solve the problems of smoking an passive smoking. The Ginkgo biloba L. leaves can be picked artificially. The cigarettes can be produced with ordinary technology. What is more important is that its
5 application can bring us great social effects and economic returns.

CLAIMS

Sub A5

1. Cigarette produced by Ginkgo biloba L. leaves, characterized in that the cigarette comprises Ginkgo biloba L. leaves as its material, if necessary, Tobacco can be optionally added therein.

2. The Ginkgo biloba L. leaves cigarette according to claim 1, wherein the cigarette contains 50wt%~100wt% Ginkgo biloba L. leaves as its material.

ABSTRACT

This invention provides a kind of cigarette substitute which is called Ginkgo Biloba L. leaves cigarette. It not only has the function of refreshing, but also is good to people's health. It avoids the harm which is brought to human bodies by the poisonous substances in tobacco. Because Ginkgo biloba L. leaves contain a large amount of flavenoids and Ginkgolide which are good to human bodies, and these pharmaceutical active ingredients are easy to volatilize and can be absorbed into lung, then good effects will be done. The smoke of this kind of cigarette is soft and dense, and it can prevent and cure hypertension, heart disease, arteriosclerosis and senile dementia disease. This kind of cigarette can be produced by ordinary technology.

09/529653

416 Rec'd PCT/PTO 17 APR 2000

Feb
Apr
9.24.00

IN THE UNITED STATES RECEIVING OFFICE

Attorney Docket No. 8737-000007

Group Art Unit:

Examiner:

Inventor: Yong Zou

Serial No.:

Filed: April 17, 2000

For: GINKGO BILOBA L.
LEAVES CIGARETTE

PRELIMINARY
AMENDMENT

Box PCT
Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

Prior to calculation of the filing fees and examination of the above-identified patent application, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Page 6, line 8, after "tobacco" please insert --or other tobacco-used herbs--; and

line 15, after "tobacco" please insert --or other tobacco-used herbs--.

Page 7, line 1, please delete "dry" and please change "flue-cure" to --dry-cured--;

line 2, after "moist-cured" please insert --, add therein different scent of

perfumes and accretions if needed--;

line 6, please delete "dry";

line 7, after "moist-cured" please insert , add therein different scent of

A₂ perfumes and accretions if needed;

line 10, please delete "dry";

line 12, after "together" please insert , add therein different scent of

A₃ perfumes and accretions if needed; and

after line 13, please add the following paragraph:

Example 4

A₄ Use processed Ginkgo biloba L. leaves 50kg, cut them into threads or pieces after moist-cured, then add wild mint or Fiveleaf Erynostemma 15kg, then blend them together, add therein different scent of perfumes and accretions if needed. By means of the ordinary process for producing cigarette, another mixed cigarette can be produced.

IN THE CLAIMS:

Please amend Claim 1 and cancel Claim 2 as follows:

A₅ 1. (Amended) Cigarette produced by Ginkgo biloba L. leaves, characterized in that the cigarette comprises Ginkgo biloba L. leaves as its material, if necessary, [Tobacco] tobacco or tobacco-used herbs can be optionally added therein, wherein the said material contains 50wt%~100wt% Ginkgo biloba L. leaves.

Please cancel Claim 2.

REMARKS

The above amendments are made to place the application in condition for examination. Entry of the amendments and examination of the application are hereby respectfully requested.

Respectfully submitted,



Thomas T. Moga
Registration No. 34,881
Attorney for Applicant

HARNESS, DICKEY & PIERCE, P.L.C.
P.O. Box 828
Bloomfield Hills, MI 48303
(248) 641-1600

Dated: April 17, 2000

TTM/trt



Attorney Docket No. 8737-000007

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

GINKGO BILOBA L. LEAVES CIGARETTE

the specification of which (check one)

☐ is attached hereto.

☒ was filed on April 17, 2000 as Application Serial No. 09/529,653 and was amended on _____
(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to the patentability of the invention claimed in this application, or information that is material to the examination of this application, in accordance with Title 37, Code of Federal Regulations, section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, section 119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)

			Priority Claim	
<u>97106146.7</u>	<u>China</u>	<u>October 17, 1997</u>	<u>X</u>	
(Number)	(Country)	(Day/Month/Year filed)	Yes	No
<u>PCTCN9800209</u>	<u>PCT</u>	<u>September 30, 1998</u>	<u>X</u>	
(Number)	(Country)	(Day/Month/Year filed)	Yes	No
_____	_____	_____	Yes	No
(Number)	(Country)	(Day/Month/Year filed)		

DECLARATION AND POWER OF ATTORNEY

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States Provisional application(s) listed below:

PRIOR PROVISIONAL APPLICATIONS

(application serial number)

(Month / Day / Year filed)

(application serial number)

(Month / Day / Year filed)

I hereby claim the benefit under Title 35, United States Code, section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.

Filing Date

**Status - patented,
pending, abandoned**

_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint Thomas T. Moga, Reg. No. 34,881, and each principal, attorney of counsel, associate and employee of Harness, Dickey & Pierce, P.L.C., who is a registered Patent Attorney, my attorney with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. I request the Patent and Trademark Office to direct all correspondence and telephone calls relative to this application to Harness, Dickey & Pierce, P.L.C., P. O. Box 828, Bloomfield Hills, Michigan 48303 (248) 641-1600.

Full name of sole or first inventor: Yong Zou

Inventor's signature: Yong Zou

Date: 2000.6.6


(June/06/2000)

Residence: Shandong Institute for Product Quality Supervision & Inspection 81, Shandabei Road, Jinan City, Shandong 250100, China

Citizenship: China

Post Office Address: same as residence

DECLARATION AND POWER OF ATTORNEY



Full name of second joint inventor, if any: Qiang Zou

Second Inventor's signature: Qiang Zou

Date: June 106 / 2000

Residence: Shandong Institute for Product Quality Supervision & Inspection 81, Shandabei Road, Jinan City, Shandong 250100, China CNY

Citizenship: China

Post Office Address: same as residence

Full name of third joint inventor, if any: _____

Third Inventor's signature: _____

Date: _____

Residence: _____

Citizenship: _____

Post Office Address: _____

Full name of fourth joint inventor, if any: _____

Fourth Inventor's signature: _____

Date: _____

Residence: _____

Citizenship: _____

Post Office Address: _____

Full name of fifth joint inventor, if any: _____

Fifth Inventor's signature: _____

Date: _____

Residence: _____

Citizenship: _____

Post Office Address: _____